Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Thomas Rojewski

Sleep Medicine Zanesville, OH Medical Doctor

NPI 1215096854 CMS profile 454832

2945 Maple Ave, Zanesville, OH 43701

Open in the dashboard

General payments

$153

6 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Thomas Rojewski of Zanesville, OH is reported in the CMS Open Payments database as having received $153 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $21 1
2020 General $54 2
2019 General $78 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Rojewski
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Thomas Rojewski were reported at $0. Among 41 Sleep Medicine profiles paid that year, the median was $509 and the middle half received between $149 and $1,143.

Show as a table
Year Thomas Rojewski Sleep Medicine median Middle half National median
2019 $78 $276 $99–$1,051 $163
2020 $54 $154 $53–$837 $114
2021 $0 $311 $144–$1,090 $132
2022 $21 $312 $80–$539 $149
2023 $0 $439 $154–$773 $160
2024 $0 $450 $149–$1,411 $164
2025 $0 $509 $149–$1,143 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Stryker Corporation $100 3 payments
  2. Jazz Pharmaceuticals Inc. $35 2 payments
  3. OptiNose US, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $153 6 payments
Products named General payments · program years 2019–2022
  1. ENTELLUS - XPRESS ENT DILATION SYSTEM $79 2 payments
  2. XPRESS ENT DILATION SYSTEM $21 1 payment
  3. Xhance $18 1 payment
  4. SUNOSI Pain $18 1 payment
  5. SUNOSI Neurology $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

169

Median for Otolaryngology: 297

Drug cost

$3,700

Median for Otolaryngology: $6,314

Branded share of claims

23.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 28 $1,387
Armodafinil Generic 19 $1,305
Fluticasone Propionate Generic 27 $376
Gabapentin Generic 49 $308
Levothyroxine Sodium Generic 14 $185
Zolpidem Tartrate Generic 21 $102
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 11 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$38,841

Medicare's payments for the services billed

Medicare patients

312

Average age 71

Services billed

548

142 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 33%
Depression 26%
Chronic kidney disease 23%
COPD 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record